A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)ide Reverse Transcriptase Inhibitors (NRTI) plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants

November 20, 2018
https://clinicaltrials.gov/ct2/show/NCT03631732
Infectious Disease
Principal Investigator: Indira Brar, MD

 Nucleos(t)ide Reverse Transcriptase Inhibitors, Bictegravir/Emtricitabine/Tenofovir Alafenamide, HIV-1

Accepting Participants